Volume | 2,245,160 |
|
|||||
News | - | ||||||
Day High | 137.22 | Low High |
|||||
Day Low | 135.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Novo Nordisk | NVO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
136.46 | 135.00 | 137.22 | 134.03 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
35,881 | 2,245,160 | $ 136.38 | $ 306,193,417 | - | 75.56 - 138.28 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:45:47 | 1 | $ 137.06 | USD |
Novo Nordisk (NVO) Options Flow Summary
Novo Nordisk Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
617.87B | 4.51B | - | 232.26B | 83.68B | 18.56 | 7.38 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Novo Nordisk News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 133.15 | 137.22 | 130.85 | 133.53 | 2,826,478 | 3.91 | 2.94% |
1 Month | 123.69 | 137.22 | 121.2902 | 128.73 | 4,027,309 | 13.37 | 10.81% |
3 Months | 120.11 | 138.28 | 118.91 | 128.83 | 4,521,034 | 16.95 | 14.11% |
6 Months | 104.30 | 138.28 | 94.7313 | 118.86 | 4,491,434 | 32.76 | 31.41% |
1 Year | 84.08 | 138.28 | 75.56 | 108.91 | 3,643,018 | 52.98 | 63.01% |
3 Years | 40.905 | 138.28 | 39.355 | 87.26 | 2,101,188 | 96.16 | 235.07% |
5 Years | 23.89 | 138.28 | 23.41 | 69.94 | 1,809,796 | 113.17 | 473.71% |
Novo Nordisk Description
Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |